Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.

NCT01458951 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01458951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01458951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2012
Completion date
June 30, 2015
Enrollment
547 (actual)
Sites
182

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis